Toregem BioPharma
PrivateLast Round
Early Funding
May 19, 2026
Total Funding Raised
$22.53M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Toregem BioPharma is a biopharmaceutical company developing regenerative therapeutics for tooth loss.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Toregem BioPharma Comparables
Compare Toregem BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OrganTech Inc. | 65% | |
| HysensBio | 61% | |
| Air Water Inc. | 54% |
Toregem BioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 19, 2026 | ||||
| Series B | Aug 30, 2024 | ||||
| Series A Extension | Jul 3, 2023 | ||||
| Series A | Mar 8, 2022 | ||||
| Seed | Apr 30, 2021 | ||||
Seed | May 12, 2020 |
Toregem BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Early Funding |
| Tohoku University Venture Partners | Series B, Series A Extension |
| JIC Venture Growth Investments | Early Funding, Series B, Series A Extension |
| Kyoto Capital Partners | Series B |
| Miraidoa | Series A |
| Astellas Venture Management | Series B, Series A Extension, Series A |
| Mitsubishi UFJ Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 19, 2026
$5.3M raised from multiple venture capital firms.
- Aug 30, 2024
$10.25M round with participation from Astellas Venture Management and SMBC Venture Capital.
Recent news
Latest coverage and updates
- hiresSep 11, 2026
Toregem BioPharma Co. hired Hiroki Wada as president and chief executive on Aug 27th '26.
Toregem BioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Toregem BioPharma's valuation, stock price, and market status.
Is Toregem BioPharma a public or private company?
Toregem BioPharma is a private company.
What is the current stock price of Toregem BioPharma?
Toregem BioPharma is a private company with no public stock price. No recent secondary market data is available.
How much is Toregem BioPharma worth (valuation)?
Valuation information for Toregem BioPharma is not publicly available.
Can I buy Toregem BioPharma stock?
Toregem BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Toregem BioPharma's last funding round?
Toregem BioPharma's most recent funding round was Series B on August 30, 2024.
Who are the main investors in Toregem BioPharma?
Key investors in Toregem BioPharma include Kyoto University Innovation Capital.
Will Toregem BioPharma IPO soon?
No public IPO plans have been announced for Toregem BioPharma.
How can I track Toregem BioPharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Toregem BioPharma's secondary market activity and sign up for updates.